Update on the Pharmacotherapy of Heart Failure with Reduced Ejection Fraction-Reference-Cited by-同舟云学术

Update on the Pharmacotherapy of Heart Failure with Reduced Ejection Fraction

Published:2020 Issue:4 Volume:2 Page:113
ISSN:2671-700X
Container-title:Cardiovascular Prevention and Pharmacotherapy
language:en
Short-container-title:Cardiovasc Prev Pharmacother

Author:

Kim Eui-Soon¹^ORCID,Youn Jong-Chan²^ORCID,Baek Sang Hong²^ORCID

Affiliation:

1. Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology, Daejeon, Korea.

2. Division of Cardiology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.

Funder

National Research Foundation of Korea

Publisher

Korean Society of Cardiovascular Disease Prevention

Subject

General Arts and Humanities

Link

https://e-jcpp.org/pdf/10.36011/cpp.2020.2.e17

Reference98 articles.

1. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

2. 2013 ACCF/AHA Guideline for the Management of Heart Failure: Executive Summary

3. Korean Guidelines for Diagnosis and Management of Chronic Heart Failure

4. Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association

5. Epidemiology of Heart Failure in Korea: Present and Future

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Eligibility and Cost-Utility Analysis of Dapagliflozin in Patients with Heart Failure Across the Whole Spectrum of Ejection Fraction in South Korea;American Journal of Cardiovascular Drugs;2024-02-27

2. Real-World Eligibility and Cost-Effectiveness Analysis of Empagliflozin for Heart Failure in Korea;Journal of Korean Medical Science;2024

3. Korean Society of Heart Failure Guidelines for the Management of Heart Failure: Treatment;Korean Circulation Journal;2023

4. Korean Society of Heart Failure Guidelines for the Management of Heart Failure: Treatment;International Journal of Heart Failure;2023

5. Characteristics, outcomes, and predictors of de novo malignancy after heart transplantation;Frontiers in Cardiovascular Medicine;2022-08-08